Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Revenue (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Revenue for 7 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 12.18% year-over-year to $3.3 million, compared with a TTM value of $21.2 million through Dec 2025, up 94.82%, and an annual FY2025 reading of $18.8 million, up 72.11% over the prior year.
  • Revenue was $3.3 million for Q4 2025 at Avidity Biosciences, down from $12.5 million in the prior quarter.
  • Across five years, Revenue topped out at $12.5 million in Q3 2025 and bottomed at $1.6 million in Q1 2025.
  • Average Revenue over 5 years is $3.0 million, with a median of $2.4 million recorded in 2022.
  • Peak annual rise in Revenue hit 434.03% in 2025, while the deepest fall reached 55.6% in 2025.
  • Year by year, Revenue stood at $1.9 million in 2021, then skyrocketed by 49.51% to $2.8 million in 2022, then fell by 20.8% to $2.2 million in 2023, then skyrocketed by 35.57% to $3.0 million in 2024, then increased by 12.18% to $3.3 million in 2025.
  • Business Quant data shows Revenue for RNA at $3.3 million in Q4 2025, $12.5 million in Q3 2025, and $3.8 million in Q2 2025.